This year's tally of biopharmaceutical initial public offerings in the US was tied with 2016's total of 30 IPOs when Rhythm Pharmaceuticals Inc. went public on Oct. 5, but 2017 outpaced last year when OptiNose Inc. launched its IPO on Oct. 12.
With 31 first-time offerings by drug developers and only two and a half months to go until 2018, this year...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?